Stereotaxis, Inc.

Stereotaxis, Inc.

STXS·AMEX

$1.84

-2.9%
HealthcareMedical - Instruments & Supplies

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

At a Glance

Live Snapshot
Market Cap$179.84M
EPS-0.2500
P/E Ratio-7.36
Earnings Date08/06/2026

stxs

Cash and Cash Equivalents

Last Annual Value

13.42M

3-Year CAGR

16%

5-Year CAGR

-21%

10-Year CAGR

9%

Stereotaxis, Inc.

Stereotaxis, Inc. Competitors Analysis of Cash and Cash Equivalents

STXS · AMEX
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.42M
-12.2%-19.1%4.7% 
CVRX logo
CVRx, Inc.
NASDAQ:CVRX
75.71M
-5.8%-11.8%N/A
XGN logo
Exagen Inc.
NASDAQ:XGN
32.22M
-4.1%-20.2%N/A
199.28K
-91.2%-72.0%-46.8%
29.84M
-44.5%-40.4%0.1%
16.58M
47.7%-2.3%34.9%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
50.50M
-14.4%-25.3%N/A
35.02M
-22.5%-9.2%N/A
159.62M
-22.5%-12.8%29.0%
230.91M
-7.5%-9.0%58.5%
Stereotaxis, Inc.

Stereotaxis, Inc. Fair Value Envelope

STXS · AMEX

Our analysis suggests that STXS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.84, this represents a potential HIDDEN relative to our calculated worth for Stereotaxis, Inc..

Intrinsic Value
Current Price: $1.84